## DOC: Healthpeak Properties, Inc. - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%); PEG 4.08 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-25 | Wells Fargo | $19 | $18 | +6% |
| 2025-11-12 | Baird | $20 | $21 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-25 | Wells Fargo | main | Equal-Weight |
| 2025-11-12 | Baird | main | Outperform |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 15.7% (-1.9%)
- Blackrock Inc.: 10.5% (-1.7%)
- JPMORGAN CHASE & CO: 8.1% (+182.0%)
- State Street Corpora: 7.1% (+1.8%)
- Principal Financial : 3.9% (-3.2%)

### Key Risks

1. Valuation risk: PEG 4.1x with declining EPS estimates leaves no margin for error.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.08 signals overvaluation risk, limited margin of safety. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.6B |
| Beta | 1.09 |
| 52W Range | $16.45 - $21.63 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.08 |
| Forward P/E | 72.8 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from 1.0% to -0.2% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.25% (CS: 58) | Neutral |
| RSI_14 | 54.9 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 0.995x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.19
- **Stop Loss:** $17.47 (4.0% risk)
- **Target:** $18.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 694
- **Position Value:** $12,623.86
- **Portfolio %:** 12.62%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-05 (Est: $0.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.06 | $-0.18 | -403.2% |
| 2025Q2 | $0.06 | $0.06 | +12.2% |
| 2025Q1 | $0.04 | $0.06 | +40.7% |
| 2024Q4 | $0.05 | $0.05 | -4.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*